Adding extended-release oxybutynin to tamsulosin resulted in greater declines in IPSS, study found
Combination therapy with tamsulosin and extended-release oxybutynin is superior to tamsulosin alone in treating men with lower urinary tract symptoms (LUTS), data show.
The finding comes from a study of 420 men aged 45 years and older. They men had a total International Prostate Symptom Score (IPSS) of 13 or more and an IPSS score for storage of 8 or more. Investigators randomly assigned patients to receive tamsulosin (0.4 mg/day) with either placebo or extended-release oxybutynin (10 mg/day) for 12 weeks. The primary end point was the change from baseline in total IPSS after 12 weeks of treatment.
After 12 weeks, total IPSS decreased by 6.9 points (from 20.2 to 13.3) in the tamsulosin plus oxybutynin arm and by 5.2 points (20.5 to 15.2) in the tamsulosin plus placebo group, the researchers reported in Mayo Clinic Proceedings (2008;83:1002-1010). The IPSS for storage decreased by 3.7 points among the dual-regimen recipients (from 10.3 to 6.5) and 2.4 points (from 10.0 to 7.6) in the tamsulosin-placebo arm. The differences between the groups were statistically significant.
The rates of study withdrawal because of adverse events were similar in both groups (about 10%).
The researchers concluded that extended-release oxybutynin (10 mg/day) “is an effective and safe adjunct to tamsulosin in men who are bothered by storage LUTS.”